29
https://pubmed.ncbi.nlm.nih.gov/38112161
This abstract reports a case of immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening disease, that occurred 45 months after a patient was treated with the anti-CD52 lymphoid cell depleting monoclonal antibody alemtuzumab for relapsing-remitting multiple sclerosis.
